



FOR IMMEDIATE RELEASE

Precision Medical Ventures announces the rebranding of Mindshare Medical to RevealDx and the appointment of Chris Wood as CEO.

Seattle, WA - September 9, 2021 - Precision Medical Ventures (PMV), an investment group led by Radiology and Health Care industry veterans, today announced the rebranding of Mindshare Medical as RevealDx. PMV acquired substantially all of the assets of Mindshare Medical in March 2021, and has focused the company on the diagnosis and treatment of Lung Cancer.

RevealDx recently completed a pivotal validation study and is expecting publication of additional validation data by the end of 2021.

Michael Calhoun, founder of Mindshare Medical, said, “As our company moves from research and development to validation and commercial delivery, we’re excited to add the expertise and successful track-record of Chris and other industry leaders. As RevealDx we’re accelerating the commercialization phase and starting to realize our mission of improving patient care.”

Chris Wood, CEO of RevealDx, said, “Our rebranding reflects our mission to inform precision medicine through radiomics. With our clinical validation nearing publication, we are focusing on building the most efficient workflow integration. Strategic partnerships will be announced soon that will accelerate that integration.”

About RevealDx

RevealDx has developed RevealAI-Lung, the world's first CADx software for the characterization of lung nodules to receive regulatory clearance. The RevealAI-Lung software has been validated with results that improve diagnostic precision and save health systems significant cost in management of lung nodules, which are found on over a third of Chest CT scans and result in > \$10B in unnecessary procedures each year in the US alone.

About Precision Medical Ventures

PMV is an investment group consisting of radiology and healthcare industry veterans, including executives and founders from PACS, Precision Medicine, CAD and MRI.

Contact: chris@reveal-dx.com